SQUAWK/NEWS
Account
Account
Menu
Live News EQUITY FLASH M impact

PVLA: FDA Starts Review

Palvella Therapeutics announces FDA rolling review of its new drug application for Qtorin Rapamycin

PVLA

This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.